Trial
NCT04746924
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
BeiGene
Collaborators
—
Condition
Non-small Cell Lung Cancer
Intervention
Tislelizumab
Why stopped
This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-12